BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20302028)

  • 1. FDG PET/CT in the detection of recurrent rectal cancer.
    Kau T; Reinprecht P; Eicher W; Lind P; Starlinger M; Hausegger KA
    Int Surg; 2009; 94(4):315-24. PubMed ID: 20302028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection.
    Even-Sapir E; Parag Y; Lerman H; Gutman M; Levine C; Rabau M; Figer A; Metser U
    Radiology; 2004 Sep; 232(3):815-22. PubMed ID: 15273334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer.
    Bellomi M; Rizzo S; Travaini LL; Bazzi L; Trifirò G; Zampino MG; Radice D; Paganelli G
    Radiol Med; 2007 Aug; 112(5):681-90. PubMed ID: 17657420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients.
    Moore HG; Akhurst T; Larson SM; Minsky BD; Mazumdar M; Guillem JG
    J Am Coll Surg; 2003 Jul; 197(1):22-8. PubMed ID: 12831920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
    Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
    AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
    Aukema TS; Rutgers EJ; Vogel WV; Teertstra HJ; Oldenburg HS; Vrancken Peeters MT; Wesseling J; Russell NS; Valdés Olmos RA
    Eur J Surg Oncol; 2010 Apr; 36(4):387-92. PubMed ID: 19962268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET/CT pattern analysis for surgical staple line recurrence in patients with colorectal cancer.
    Shyn PB; Madan R; Wu C; Erturk SM; Silverman SG
    AJR Am J Roentgenol; 2010 Feb; 194(2):414-21. PubMed ID: 20093604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
    Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
    Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer.
    Gearhart SL; Frassica D; Rosen R; Choti M; Schulick R; Wahl R
    Ann Surg Oncol; 2006 Mar; 13(3):397-404. PubMed ID: 16485158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET.
    Schaffler GJ; Wolf G; Schoellnast H; Groell R; Maier A; Smolle-Jüttner FM; Woltsche M; Fasching G; Nicoletti R; Aigner RM
    Radiology; 2004 Jun; 231(3):858-65. PubMed ID: 15105451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U; You J; McSweeney S; Freeman M; Hendler A
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
    Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
    Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-avid presacral soft tissue mass in previously treated rectal cancer: Diagnostic outcome and additional value of MRI, including diffusion-weighted imaging.
    Pennings JP; de Haas RJ; Murshid KJA; de Jong KP; Dierckx RAJO; Kwee TC
    Eur J Surg Oncol; 2019 Apr; 45(4):606-612. PubMed ID: 30594404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
    Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
    J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.